Debiopharm Releases Results of 3 Key Oncology Compound Programs at the 2019 American Association for Cancer Research (AACR) Conference in Atlanta, GA

Debiopharm announces the poster presentations of preclinical data for Debio 0123 and clinical data for Debio 1143 and Debio 1347

News provided by

Debiopharm International SA

Apr 01, 2019, 08:33 ET

LAUSANNE, Switzerland, April 1, 2019 /PRNewswire/ -- Debiopharm, (www.debiopharm.com/debiopharm-international/) a global biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including pre-clinical results of Debio 0123 (Selective WEE1 inhibitor), diagnostic molecular screening for Debio 1347 (FGFR inhibitor) and clinical exploratory results for Debio 1143 (IAP1 inhibitor) at the 2019 Annual AACR meeting in Atlanta, Georgia. These abstract presentations are part of Debiopharm's ongoing oncology programs to investigate the anti-tumor activity and toxicity profile of innovative compounds aimed at treating a broad variety of cancer types.

"These results from our multiple ongoing oncology programs are giving us more insight into the potential of integrating specialized, targeted compounds into current therapeutic strategies."
- Gregoire Vuagniaux, Director of Translational Pharmacology, Debiopharm International SA

AACR 2019 Abstract Presentations

Compound

Title

Date and Time

N°

Debio 0123

Antitumor activity of the novel oral highly
selective Wee1 inhibitor Debio 0123

 

Tue, April 2nd,
1:00-5:00pm

#4423

 

Debio 1143

Open-label, exploratory pre-operative window-
of-opportunity trial to investigate the pharmacokinetics
and pharmacodynamics of the SMAC mimetic Debio
1143 in patients with resectable squamous cell
carcinoma of the head and neck

Wed, April 3rd,
8:00-12:00pm

#5001

 

Debio 1347

Molecular screening of patients with FGFR
alterations for a phase 1 (ph1) study with the
selective FGFR inhibitor (FGFRi) DEBIO 1347

Wed, April 3rd,
8:00-12:00pm

Section 19

#4881

 

Debiopharm International's commitment to cancer patients
Debiopharm International SA aims to develop innovative therapies that target high unmet medical needs in oncology. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing and clinical development and then select large pharmaceutical commercialization partners to maximize patient access across the globe.

Find out about our currently clinical trials at patients.debiopharm.com 
Visit us www.debiopharm.com/debiopharm-international/ 
Follow us @DebiopharmNews at twitter.com/DebiopharmNews

Debiopharm International SA Contact
Dawn Haughton
Communication Manager
[email protected] 
Tel: +41 (0)21 321 01 11

____________________
1 IAP= Inhibitor of Apoptosis Proteins

SOURCE Debiopharm International SA

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED